Gilla Kaplan Sells 9,250 Shares of Celgene Corporation (CELG) Stock
Celgene Corporation (NASDAQ:CELG) Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Gilla Kaplan also recently made the following trade(s):
- On Wednesday, August 2nd, Gilla Kaplan sold 7,500 shares of Celgene Corporation stock. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00.
Shares of Celgene Corporation (NASDAQ CELG) traded down 0.50% during midday trading on Thursday, reaching $140.55. The company’s stock had a trading volume of 3,074,739 shares. Celgene Corporation has a one year low of $96.93 and a one year high of $142.64. The stock’s 50 day moving average price is $134.74 and its 200 day moving average price is $127.31. The firm has a market cap of $109.96 billion, a price-to-earnings ratio of 43.53 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the company posted $1.44 EPS. The business’s revenue was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.
CELG has been the subject of several research analyst reports. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $98.00 price objective (up previously from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $134.80 price objective for the company in a report on Wednesday, May 17th. Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Monday, May 22nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $152.00 price objective on shares of Celgene Corporation in a report on Tuesday, May 23rd. Finally, Credit Suisse Group set a $148.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a report on Monday, May 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and an average target price of $147.31.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. raised its position in shares of Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the 1st quarter valued at approximately $118,000. Motco raised its position in shares of Celgene Corporation by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Penserra Capital Management LLC purchased a new stake in shares of Celgene Corporation during the 2nd quarter valued at approximately $129,000. Finally, Oakworth Capital Inc. raised its position in shares of Celgene Corporation by 60.9% during the 1st quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the period. 79.43% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.